New RNA vaccine aims to stop breast cancer return
Disease control
Recruiting now
This early-stage trial tests an investigational cancer vaccine called ITI-5000 in 60 people with stage II-III triple-negative breast cancer who have finished standard treatment. The vaccine uses self-amplifying RNA to teach the immune system to attack cancer cells. The study firs…
Phase: PHASE1 • Sponsor: Immunomic Therapeutics, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC